Gout is the lesion incurred by urate crystallization and sedimentation around the joint and in subcutaneous tissue, skeleton and urinary tract caused due to purine metabolic disorders.
There has been no definite and effective therapeutic method for gout in the medical community all the time, and currently the consensus is to simply take colchicine tablets and allopurinol, which cause relatively large damage to stomach and intestine as well as kidney, and cannot cure it after repeated attacks.
There was a piece of very exciting news for the patients with gout from the Chinese gout academic workshop held in Beijing a few days ago: based on the essence of Tibetan medication in treating gout, the new drug for gout developed by the Chinese gout tackling team finally achieved success after nearly 5 years of clinical trial on 2236 cases of patients with gout. The clinical observation proved that: effective components of the drug can decompose the gout calculus depositing in each part in vivo for a long time into water, carbon dioxide and soluble sodium salt, which will be eliminated from the body by urine, to avoid re-sedimentation forming calculus, thus achieving the purpose of cure.
The drug has been approved by CFDA as a therapeutic pharmaceutical product with a Chinese drug approval number, which has overcome the problem of the long resistance to treatment of repeated attack of gout. The drug will show efficacy in 3-7 days after being taken, clinical cure in 2-3 treatment courses, and bring back the healthy life in 5-6 treatment courses.
